Filing Flows › Boston Scientific (BSX) › Capital expenditures
Boston Scientific (BSX) capital expenditures by quarter
Boston Scientific's capital expenditures were $180M in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 7 quarters it ranged from $157M (Q2 2025) to $351M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $180M | -8% | -0.6% |
| Q2 2026 | $195M | +10% | +24% |
| Q1 2026 | $177M | -50% | -5% |
| Q4 2025 | $351M | +94% | — |
| Q3 2025 | $181M | +15% | — |
| Q2 2025 | $157M | -16% | — |
| Q1 2025 | $187M | — | — |
Q3 2026 at a glance
Boston Scientific, Q3 2026: revenue $5.1B (+1% year over year), operating margin 16.1%, net earnings $580M, operating cash flow $1.0B. The chart follows the revenue to costs, profit and cash.
Questions
What is Boston Scientific's capital expenditures?
Boston Scientific's capital expenditures were $180M in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has Boston Scientific's capital expenditures changed?
Over the last 7 quarters it ranged from $157M (Q2 2025) to $351M (Q4 2025).